Synthetic Biologics Inc (SYN)

0.62
0.01 1.40
AMEX : Health Care
Prev Close 0.63
Open 0.65
Day Low/High 0.61 / 0.66
52 Wk Low/High 0.93 / 3.45
Volume 462.90K
Avg Volume 1.10M
Exchange AMEX
Shares Outstanding 121.89M
Market Cap 65.82M
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Synthetic Biologics Reports Preclinical Data Demonstrating SYN-005 Provides Protection From Pertussis In Neonatal Animal Study

Synthetic Biologics Reports Preclinical Data Demonstrating SYN-005 Provides Protection From Pertussis In Neonatal Animal Study

-- Study Results Further Support Advancement of SYN-005 into Clinical Trials for Treatment and Prevention of Pertussis --

Synthetic Biologics To Report 2016 Year End Operational Highlights And Financial Results On March 2, 2017

Synthetic Biologics To Report 2016 Year End Operational Highlights And Financial Results On March 2, 2017

-- Conference Call Scheduled for Thursday, March 2, 2017 at 4:30 p.m. EST --

Synthetic Biologics Confirms Key Features Of Pivotal Phase 2b/3 Trial Of SYN-010 Pursuant To Consultations With FDA

Synthetic Biologics Confirms Key Features Of Pivotal Phase 2b/3 Trial Of SYN-010 Pursuant To Consultations With FDA

-- Enrollment in SYN-010 Pivotal Trial Will Be Open to All IBS-C Patients --

Synthetic Biologics' SYN-004 (ribaxamase) Achieves Primary Endpoint In Phase 2b Trial For C. Difficile Infection (CDI)

Synthetic Biologics' SYN-004 (ribaxamase) Achieves Primary Endpoint In Phase 2b Trial For C. Difficile Infection (CDI)

-- Presentation Planned for 9:30am (PT), Jan. 9, 2017 at Biotech Showcase in San Francisco --

Synthetic Biologics Announces Granting Of U.S. Composition Of Matter Patent For SYN-005, Designed For The Treatment And Prevention Of Pertussis (Whooping Cough)

Synthetic Biologics Announces Granting Of U.S. Composition Of Matter Patent For SYN-005, Designed For The Treatment And Prevention Of Pertussis (Whooping Cough)

- Granted Patent Provides Composition of Matter Protection for SYN-005 to at Least 2035 -

Synthetic Biologics To Report Third Quarter 2016 Operational Highlights And Financial Results On November 1, 2016

Synthetic Biologics To Report Third Quarter 2016 Operational Highlights And Financial Results On November 1, 2016

-- Conference Call Scheduled for Tuesday, November 1, 2016 at 8:30 a.m. EDT --

Synthetic Biologics Awarded Research Contract From Centers For Disease Control And Prevention (CDC) For Microbiome Assessment And Intervention To Address Antibiotic Resistance

Synthetic Biologics Awarded Research Contract From Centers For Disease Control And Prevention (CDC) For Microbiome Assessment And Intervention To Address Antibiotic Resistance

-- Funding to Support Ongoing Phase 2b Study to Determine SYN-004's (ribaxamase) Ability to Prevent the Emergence of Antibiotic-Resistance in the Gut Microbiome of Study Participants --

7 Stocks Under $10 Making Big Moves Higher

7 Stocks Under $10 Making Big Moves Higher

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

5 Stocks Under $10 That Could Make You a Lot of Money

5 Stocks Under $10 That Could Make You a Lot of Money

These under-$10 stocks are within range of triggering big breakouts. Here's how to trade them now.

European Markets Slide as Oil Prices Fall

European Markets Slide as Oil Prices Fall

Syngenta shares surge after ChemChina takeover receives U.S. security clearance.

European Markets Up; Syngenta Surges on ChemChina Security Approval

European Markets Up; Syngenta Surges on ChemChina Security Approval

U.S. futures up as miners drop with commodities.

Synthetic Biologics Announces Completion Of End Of Phase 2 Meeting With FDA For SYN-010, Intended For The Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C)

Synthetic Biologics Announces Completion Of End Of Phase 2 Meeting With FDA For SYN-010, Intended For The Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C)

-- FDA Provides Company with Recommendation and Guidance for Clinical Study Design for Phase 2b/3 Adaptive Trial --

Synthetic Biologics Announces Granting Of European And U.S. Composition Of Matter Patents For Ribaxamase

Synthetic Biologics Announces Granting Of European And U.S. Composition Of Matter Patents For Ribaxamase

-- First Granted Patent in Europe Directly Related to Ribaxamase, intended to Prevent C. difficile Infection, Antibiotic-Associated Diarrhea and the Emergence of Antibiotic-Resistant Organisms --

Synthetic Biologics Receives USAN Approval For Generic Name Ribaxamase For Phase 2 Drug Candidate SYN-004

Synthetic Biologics Receives USAN Approval For Generic Name Ribaxamase For Phase 2 Drug Candidate SYN-004

-- Ribaxamase Designed for the Prevention of C. difficile Infection, Antibiotic-Associated Diarrhea & the Emergence of Antibiotic-Resistant Organisms --

Synthetic Biologics Announces Detailed Data From Two SYN-010 Phase 2 Clinical Trials For The Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C)

Synthetic Biologics Announces Detailed Data From Two SYN-010 Phase 2 Clinical Trials For The Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C)

-- Phase 2 Clinical Trials Demonstrate Potential of SYN-010 to Reduce Abdominal Pain and Bloating, and Improve Stool Frequency and Quality of Life Scores without Severe Adverse Events in IBS-C Patients --

Synthetic Biologics To Host Post-DDW 2016® Conference Call To Recap SYN-010 Phase 2 Clinical Trial Results For The Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C)

Synthetic Biologics To Host Post-DDW 2016® Conference Call To Recap SYN-010 Phase 2 Clinical Trial Results For The Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C)

-- Mark Pimentel, MD, FRCP(C) to Review IBS-C Patient Data from Two SYN-010 Phase 2 Clinical Trials --

Synthetic Biologics Announces Positive Topline Results From Second Phase 2a Clinical Trial Of SYN-004 For The Prevention Of C. Difficile Infection And Antibiotic-Associated Diarrhea

Synthetic Biologics Announces Positive Topline Results From Second Phase 2a Clinical Trial Of SYN-004 For The Prevention Of C. Difficile Infection And Antibiotic-Associated Diarrhea

-- SYN-004 Degraded IV Ceftriaxone in the Presence of a Proton Pump Inhibitor in the Gastrointestinal Tract without Affecting Antibiotic Levels in the Bloodstream --

Isaac J. Bright, MD, Joins Synthetic Biologics As Vice President, Corporate Development

Isaac J. Bright, MD, Joins Synthetic Biologics As Vice President, Corporate Development

-- Company Expands Strategic Partnering Efforts of Late-Stage GI Microbiome-Focused Clinical Programs --

Synthetic Biologics Appoints Deb Mathews, PharmD, As Vice President, Medical Affairs

Synthetic Biologics Appoints Deb Mathews, PharmD, As Vice President, Medical Affairs

-- Appointment Reflects Company's Late-Stage Clinical Focus and Plans to Prepare for Commercialization --